Maxygen Inc. signed a deal with F. Hoffmann-La Roche Ltd. focused on Maxygen's interferon alpha and beta variants portfolio. At this point, Roche has rights to candidates for hepatitis B and C, but if it takes its option on other indications, the deal's value could blossom to more than $230 million. (BioWorld Today) Read More